Login / Signup

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.

Lawrence BlondeTimothy S BaileyJason ChaoTerry A DexJuan Pablo FriasLuigi F MeneghiniMichelle RobertsVanita R Aroda
Published in: Advances in therapy (2019)
Sanofi US, Inc.
Keyphrases
  • glycemic control
  • type diabetes
  • weight loss
  • insulin resistance
  • clinical trial
  • phase iii
  • phase ii
  • skeletal muscle